Los Angeles, California – Arcutis Biotherapeutics, Inc. recently held its Q3 2024 Earnings Conference Call on November 6th at 4:30 PM ET. The company provided an overview of its financial results and business update for the third quarter of 2024. Present on the call were key figures from Arcutis, including Latha Vairavan, Vice President of Finance and Investor Relations, Frank Watanabe, President and CEO, Todd Edwards, Chief Commercial Officer, Patrick Burnett, Chief Medical Officer, and David Topper, Chief Financial Officer.

During the conference call, attendees included analysts such as Vikram Purohit from Morgan Stanley, Seamus Fernandez from Guggenheim Securities, Uy Ear from Mizuho, Serge Belanger from Needham & Co., and Kambiz Yazdi from Jefferies. The call began with an introduction by Vairavan, who welcomed participants and directed them to the company’s website for presentation slides. She also highlighted the importance of examining the company’s filings with the Securities and Exchange Commission for a comprehensive understanding of their business and risk factors.

Watanabe then took the floor to provide an overview of the company’s performance during the third quarter, emphasizing key highlights. He mentioned that Arcutis had maintained its momentum and outlined specific achievements. The executives present on the call discussed forward-looking statements but cautioned that they were subject to risks and uncertainties. They encouraged investors to refer to regulatory filings for a more thorough analysis.

Overall, the conference call provided valuable insights into Arcutis Biotherapeutics’ financial standing and strategic direction. The executives’ presentations and discussions offered a glimpse into the company’s growth trajectory and future prospects. Investors and analysts were able to gain a deeper understanding of Arcutis’ position in the market and its plans for the upcoming quarters.